Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016

Cited by 1,016 works. doi:10.1016/s1470-2045(16)00150-9 Open-access PDF

Authors

References